New board appointment at Orexigen
This article was originally published in Scrip
Orexigen Therapeutics, a US biopharmaceutical company focused on the treatment of obesity, has elected Dr Peter Honig to its board of directors. Dr Honig has more than 20 years' clinical and regulatory policy experience from past roles with Merck & Co and the US FDA. Most recently, he was senior vice-president of worldwide regulatory affairs and product safety at Merck and co-chair of Merck's late development review committee, overseeing the company's late-stage pipeline.